Table 2.
Icotinib in first-, second-, and third-line therapy and above
| Study | Number of Cases | Proportion of first-line therapy | OR | DCR | RR/DCR in first-line therapy | PFS, months | OS, months | Rash | Diarrhea | Dysfunction of liver |
|---|---|---|---|---|---|---|---|---|---|---|
| Song et al27 | 49 | 38.8% | 38.7% | 77.4% | – | 8.5 | – | 38.8% | 24.5% | – |
| Gu et al28 | 89 | 19.1% | 36% | 69.7% | – | – | – | 33.7% | 16.9% | 5.6% |
| Sun29 | 23 | 39% | 39.1% | 69.6% | 66.7%*/77.8% | – | – | 8.7% | 8.7% | 0% |
| Zeng et al30 | 67 | 23.9% | 35.8% | 74.6% | 56.3%*/93.8% | – | – | 20.9% | 11.9% | 1.5% |
| Zhang et al31 | 50 | 44% | 44% | 82% | 63.6%*/78.6% | – | – | 28% | 16% | 4% |
| Sun et al32 | 17 | 52.9% | 52.9% | 88.2% | 66.7%*/88.2% | – | – | 11.8% | 11.8% | 0% |
| Li et al33 | 59 | 33.9% | 45.8% | 74.6% | 40%/75% | – | – | 35.6% | 15.3% | 5.1% |
| Yu et al34 | 30 | 33.7% | 56.7% | 80% | 63.5%/72.7% | – | – | 60% | 33.3% | 16.7% |
| Wu et al35 | 42 | 40.5% | 26.2% | 78.6% | 29.4%/82.4% | 3.8 | 5.2 | 23.8% | 9.5% | 7.1% |
| Wang et al36 | 66 | 51.5% | 38.7% | 77.4% | 50%/86.7% | 7 | – | 40.9% | 18.2% | 1.5% |
Notes: “–”, not available;
*
ORR in first-line therapy was significantly higher than that in second-line therapy and above.
Abbreviations: DCR, disease control rate; OS, overall survival; PFS, progression-free survival.